Everything below concerns incretin. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Updated 2026-02-22. Numbers and descriptions here follow the published literature rather than marketing material.
Receptor activation produces downstream effects that differ by tissue. GLP-1 receptor signaling influences appetite regulation and insulin secretion in a glucose-dependent manner. GIP receptor activity contributes to metabolic handling of nutrients and may modulate adipose tissue. Glucagon receptor engagement raises energy expenditure and promotes hepatic lipid turnover, though the balance among these actions in humans is still being characterized. Preclinical models showed reductions in body weight and improved glycemic markers.
Clinical development has progressed through phase 2 trials in adults with obesity and type 2 diabetes, with phase 3 programs reported as ongoing. Reported outcomes include reductions in body weight and improvements in glycemic measures over defined treatment periods. Whether these effects translate into durable benefits after treatment ends remains an open question. Long-term safety data across broad populations are not yet complete, and regulatory decisions have not been announced.
Retatrutide is a synthetic peptide developed as a single molecule that activates three distinct hormone receptors: GLP-1, GIP, and glucagon. The compound carries the internal designation LY3437943 and was engineered by modifying the backbone of glucose-dependent insulinotropic polypeptide. Its sequence incorporates non-natural amino acids and a fatty acid side chain that extends circulation time. The triple-agonist design aims to combine appetite suppression, improved insulin response, and increased energy expenditure in one agent. Published reports describe it as an investigational product rather than an approved medicine.
Each receptor contributes a different physiological effect. Activation of the GLP-1 receptor slows gastric emptying and reduces appetite signaling in the brain. GIP receptor activity influences insulin secretion and lipid handling, while glucagon receptor stimulation raises energy use and fat oxidation. Combining these pathways is intended to produce weight loss beyond what single- or dual-receptor agonists achieve. Researchers attribute the observed potency to simultaneous engagement of all three targets, though the exact contribution of each receptor to overall effect remains under investigation.
| Property | Value | Notes |
|---|---|---|
| Receptor targets | GIP, GLP-1, glucagon | One molecule activates all three pathways |
| Research identifier | LY3437943 | Code used in published trial reports |
| Development stage | Phase 3, reported as ongoing | Not approved by any regulatory agency |
| Route studied | Subcutaneous | Administration form used in clinical trials |
| Studied populations | Adults with obesity or type 2 diabetes | Enrollment criteria vary between trials |
Clinical studies have reported notable reductions in body weight among participants. Early trials measured safety and explored several dose levels, and later studies tracked body-weight change over months of treatment. Investigators also monitor effects on glycemic markers, liver fat, and blood lipids. Because the compound is still in development, questions about long-term safety, cardiovascular outcomes, and durability after treatment ends remain open.
The three-receptor design places retatrutide in a distinct category relative to older incretin-based therapies. Single agonists target one receptor, and dual agonists target two. Adding a third target broadens the pharmacological footprint and introduces new trade-offs among efficacy, tolerability, and glucose control. How these trade-offs resolve in large trials is a central focus of current research.
Retatrutide is an investigational peptide studied for obesity and type 2 diabetes. It is a single synthetic molecule designed to activate three metabolic receptors simultaneously. The compound belongs to the incretin mimetic family, a group of peptides that imitate gut hormones involved in appetite and glucose control. Its research code is LY3437943, and it remains under clinical study rather than cleared for routine medical use.
Retatrutide is an investigational synthetic peptide developed under the code LY3437943, with a backbone derived from glucose-dependent insulinotropic polypeptide. Several non-proteinogenic residues, including alpha-aminoisobutyric acid, appear in that backbone, and a fatty diacid side chain attached through a linker extends circulation time. The molecule carries roughly thirty-nine amino acid units and a total mass near 4.7 kilodaltons. Administration is by subcutaneous injection once weekly. Published work uses both the name retatrutide and the code LY3437943.
Pharmacologically the compound activates three receptors: GLP-1, GIP, and glucagon. GLP-1 and GIP signaling contribute to glucose-dependent insulin release, delayed gastric emptying, and reduced appetite, while glucagon receptor activation is associated with increased energy expenditure and hepatic fat oxidation. The single-molecule design is intended to keep these activities in one peptide rather than combining separate agents. Relative activity at each receptor differs, and the balance between them is a central question in interpretation. The glucagon component is partly offset by incretin-mediated insulin secretion, an interaction that remains incompletely characterized.
开发进程从早期单次和多次给药研究推进至大规模后期试验。公开报告显示，参与者在体重和相关代谢指标上出现变化，但完整数据需经同行评审并接受独立复核。试验设计通常包括随机、双盲和对照设置，以区分药物效应与行为干预。监管提交和标签范围尚未确定；长期维持效果与心血管结局仍是开放问题。
与仅靶向单一受体的同类药物相比，瑞他鲁肽增加胰高血糖素受体成分，理论上可提高能量消耗并改变脂肪分布。临床中观察到的体重变化是否主要来自该额外机制，目前尚无定论。胃肠道反应是该类药物常见不良事件，试验中通过剂量递增和监测进行管理。停药后体重反弹、个体差异和长期耐受性仍需更多数据。
Saturated fatty acids have no C=C double bonds. They have the formula CH3(CH2)nCOOH, where n is some positive integer. An important saturated fatty acid is stearic acid (n = 16), which when neutralized with sodium hydroxide is the most common form of soap.
A majority of Generation Z live in urban areas and are less inclined to change address than their predecessors. Similar to the Millennials, roughly two thirds of Generation Z come from households of married parents. By contrast, this living arrangement was essentially the norm for Generation X and the Baby Boomers, at 73% and 85%, respectively. As a demographic cohort, Generation Z is smaller than the Baby Boomers or their children, the Millennials. (See population pyramid.) According to the U.S. Census Bureau, Generation Z makes up about one quarter of the U.S. population. This demographic change could have social, cultural, and political implications for the decades ahead. Generation Z are usually the children of Generation X, and sometimes Millennials. Jason Dorsey, who works for the Center of Generational Kinetics, observed that Generation Z is not an extreme version of the Millennials but is rather different, and the differences can largely be attributed to parenting. Like parents from Generation X, members of Generation Z tend to be autonomous and pessimistic. They need validation less than the Millennials and typically become financially literate at an earlier age as many of their parents bore the full brunt of the Great Recession.
Immediate-release hydrocodone with paracetamol (acetaminophen) (Vicodin, Lortab, Lorcet, Maxidone, Norco, Zydone) Immediate-release hydrocodone with ibuprofen (Vicoprofen, Ibudone, Reprexain) Immediate-release hydrocodone with aspirin (Alor 5/500, Azdone, Damason-P, Lortab ASA, Panasal 5/500) Controlled-release hydrocodone (Hysingla ER by Purdue Pharma, Zohydro ER) Hydrocodone is not available in parenteral or any other non-oral forms.
Sources: en.wikipedia.org
C. Judson King is an American chemical engineer, researcher, administrator and educator. He is professor emeritus at University of California, Berkeley, and UC universitywide provost and senior vice president of academic affairs, emeritus, at University of California. He is the former director of Center for Studies in Higher Education and the former dean of College of Chemistry at UC Berkeley. King's research has been focused in two areas: chemical engineering and higher education. In the area of chemical engineering, he has conducted considerable research on spray drying, freeze drying, and removal and recovery of organic pollutants from wastewater streams. In the area of higher education he has written about university structure and governance, innovation in universities, and engineering education. He has written three books and over 250 scientific articles. He holds 13 patents. King has received many awards for his contribution to the field of chemical engineering. He was elected to the National Academy of Engineering in 1981 for distinguished contributions to freeze-drying technology, systematic studies of chemical-process synthesis, and chemical engineering education. He became a fellow of the American Institute of Chemical Engineers in 1983, and a fellow of the American Association for the Advancement of Science in 1993. In 2009, the American Institute of Chemical Engineers named him one of the 100 Chemical Engineers of the Modern Era.
The British Colonial Secretary, Joseph Chamberlain, though sympathetic to the ultimate goals of the raid, realized it would be a mistake since the uitlanders were not supportive. He immediately tried to stop it, remarking that "if this succeeds it will ruin me. I'm going up to London to crush it". He rushed back to London and ordered Sir Hercules Robinson, governor of the Cape Colony, to repudiate the actions of Jameson and warned Rhodes that the company's charter would be in danger if it were discovered the Cape Prime Minister was involved in the raid. Chamberlain therefore instructed local British representatives to call on British colonists not to offer any aid to the raiders.
primary transcript The unprocessed, single-stranded RNA molecule produced by the transcription of a DNA sequence as it exists before post-transcriptional modifications such as alternative splicing convert it into a mature RNA product such as an mRNA, tRNA, or rRNA. A precursor mRNA or pre-mRNA, for example, is a primary transcript which, after processing, becomes a mature mRNA ready for translation.
Sources: en.wikipedia.org
==== Malaria ==== The President's Malaria Initiative, started with help from George W. Bush, has contributed to a more than 60% reduction in malaria deaths, saved 7.6 million lives, and prevented 1.5 billion malaria cases globally between 2000 and 2019. PMI has supported malaria prevention and control for over 500 million at-risk people in Africa. However, the USAID funding of PMI has been cut an estimated 47% as of June 2025. In countries such as the Democratic Republic of the Congo (DRC), these funds had supported the supply of antimalarial drugs to numerous health zones, including preventive treatments for pregnant women. Health officials in the DRC reported that the effects of these cuts were already being felt, with increased risk of severe illness and death from malaria among vulnerable populations. Former aid workers and experts also expressed concern that reduced funding undermined disease surveillance systems that help detect malaria and other outbreaks early. Such surveillance not only protects affected countries but also contributes to U.S. health security by limiting the global spread of disease. Aid organizations also highlighted how these cuts create a "vicious cycle," with malnutrition and malaria reinforcing one another. Reductions in U.S. support for nutrition programs increase children's vulnerability to malaria and other diseases, while higher malaria infections can worsen malnutrition.
Aminoglycoside is a medicinal and bacteriologic category of traditional Gram-negative antibacterial medications that inhibit protein synthesis and contain as a portion of the molecule an amino group-containing sugar. The term can also refer more generally to any organic molecule that contains amino sugar substructures. Aminoglycoside antibiotics display bactericidal activity against Gram-negative aerobes and some anaerobic bacilli where resistance has not yet arisen but generally not against Gram-positive and anaerobic Gram-negative bacteria. Streptomycin is the first-in-class aminoglycoside antibiotic. It is derived from Streptomyces griseus and is the earliest modern agent used against tuberculosis. Streptomycin lacks the common 2-deoxystreptamine moiety (image right, below) present in most other members of this class. Other examples of aminoglycosides include the deoxystreptamine-containing agents kanamycin, tobramycin, gentamicin, and neomycin (see below).
=== Blood plasma and serum === In addition to purified proteins, DSC has been applied to unfractionated blood plasma and serum; the diluted fluid is measured directly, without labeling. The resulting curve, called a thermogram, approximates the sum of the combined denaturation profiles of the most abundant plasma proteins, weighted by their concentrations. Because these proteins interact, the additivity is not exact. For plasma from healthy donors scanned at 1 °C per minute, three independant research groups reported a fibrinogen transition at about 51 °C, a dominant albumin peak near 62–63 °C, immunoglobulin and other globulin transitions between roughly 68 and 75 °C, and a weak transferrin transition at about 85 °C. Serum exhibits a similar profile, except that the fibrinogen transitions are absent. Calorimetric measurements of serum and plasma from cancer patients were documented as early as the 1990s by a team in Tbilisi, who observed broadened heat-absorption curves shifted toward higher temperatures compared to healthy controls. From 2007, Chaires, Garbett and colleagues at the University of Louisville reported that plasma from healthy individuals gave a characteristic, reproducible thermogram. Samples from patients with cervical cancer, Lyme disease, rheumatoid arthritis or systemic lupus erythematosus displayed altered profiles.
Sources: en.wikipedia.org
It is a synthetic peptide triagonist that engages GIP, GLP-1, and glucagon receptors. Investigational compounds in this class are studied for metabolic conditions rather than for a single organ system.
No regulatory agency has approved it for any indication. It remains an investigational product studied within controlled clinical trial programs.
A dual agonist engages two receptor targets, typically GIP and GLP-1. A triagonist adds glucagon receptor activity, which is intended to influence energy expenditure alongside appetite and glucose handling.
Retatrutide is an investigational peptide that activates the GLP-1, GIP, and glucagon receptors at the same time. It is being studied for obesity and type 2 diabetes and has not been approved for clinical use. The internal code LY3437943 refers to the same molecule.